<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="2; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; TMPRSS2, Transmembrane" exact="Serine" post="Protease 2. After binding to ACE2, the cellular transmembrane"/>
 <result pre="the absence of anti-inflammatory agents (see below). In some patients," exact="tacrolimus" post="reduction may be preferred over complete withdrawal (67, 69)"/>
 <result pre="showed no benefit compared to control group (87) Chloroquine/Hydroxychloroquine Â±" exact="azithromycin" post="Increases endosomal pH Not reduced risk of death in"/>
 <result pre="548 patients (93). In a retrospective study on 201 patients" exact="methylprednisolone" post="was beneficial in those with severe disease (94) IVIg"/>
 <result pre="with target membrane Not improvement in a retrospective study (99)" exact="Bromhexine" post="hydrochloride Transmembrane protease serine inhibitor Ongoing trials Danoprevir HCV"/>
 <result pre="Broad spectrum antivirals RCT proved benefit in triple therapy (101)" exact="Nitric Oxide" post="Gas Inhibits viral protein and RNA synthesis Ongoing trials"/>
 <result pre="NLRP3 inflammasome Ongoing trials Fingolimod Sphingosine-1-phosphate receptor regulator Ongoing trials" exact="Naproxen" post="Inhibitor of both COX-2 of Influenza A virus NP"/>
 <result pre="NP Ongoing trials Pirfenidone Inhibits IL-1Î² and IL-4 Ongoing trials" exact="Ruxolitinib" post="JAK 1 and JAK 2 inhibitor Ongoing trials Sarilumab"/>
 <result pre="monoclonal Ab Decrease inflammatory markers in a retrospective study (104)" exact="Thalidomide" post="Reduces TNFÎ± Ongoing trials Ulinastatin Reduces TNFÎ±, IL-6, and"/>
 <result pre="animal models (109, 110). Lopinavir is used in combination with" exact="ritonavir" post="because it increases the plasma half-life of lopinavir inhibiting"/>
 <result pre="combination with ritonavir because it increases the plasma half-life of" exact="lopinavir" post="inhibiting the cytochrome P450 (111). Despite these promising results,"/>
 <result pre="alone in the time to clinical improvement or mortality (87)." exact="Hydroxychloroquine" post="SARS-CoV-2 needs an acidic endosomal pH for processing and"/>
 <result pre="internalization (8). In vitro data indicate that the antimalarial drug" exact="chloroquine" post="exerts antiviral effects by increasing endosomal pH and abrogating"/>
 <result pre="pH and abrogating virus-endosome fusion. Antiviral effects in vivo of" exact="hydroxychloroquine" post="may be enhanced by the immune-modulating activity that this"/>
 <result pre="efficacy of hydroxychloroquine, particularly combined with azithromycin, in viral clearance." exact="Hydroxychloroquine" post="is often administered in conjunction with azithromycin, but caution"/>
 <result pre="of 62 COVID-19 positive patients (not peer-reviewed) patients treated with" exact="hydroxychloroquine" post="treatment showed an improvement in the clinical recovery and"/>
 <result pre="one observational study of 1,376 patients with COVID-19 treated with" exact="hydroxychloroquine" post="showed no difference in the risk of being intubated"/>
 <result pre="intubated or death compared to patients who did not receive" exact="hydroxychloroquine" post="(88). The quick evolution of the COVID-19 pandemic and"/>
 <result pre="Remdesivir Remdesivir has broad-spectrum antiviral activity because it is an" exact="adenosine" post="analog that can determine pre-mature termination of viral RNA"/>
 <result pre="of COVID-19. JAK-STAT Inhibitors JAK-STAT inhibitors, like baricitinib, fedratinib, and" exact="ruxolitinib" post="are potent anti-inflammatory drugs that are approved for rheumatoid"/>
 <result pre="and recommendations. Lancet Respir Med. (2020) 8:506â€&quot;17. 10.1016/S2213-2600(20)30161-232272080 34.GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.." exact="Hydroxychloroquine" post="and azithromycin as a treatment of COVID-19: results of"/>
 <result pre="Lancet Respir Med. (2020) 8:506â€&quot;17. 10.1016/S2213-2600(20)30161-232272080 34.GautretPLagierJCParolaPHoangVTMeddebLMailheMet al.. Hydroxychloroquine and" exact="azithromycin" post="as a treatment of COVID-19: results of an open-label"/>
 <result pre="J Med. (2020) 382:1787â€&quot;99. 10.1056/NEJMoa200128232187464 88.GelerisJSunYPlattJZuckerJBaldwinMHripcsakGet al.. Observational study of" exact="hydroxychloroquine" post="in hospitalized patients with Covid-19. N Engl J Med."/>
 <result pre="print]. 101.HungIFNLungKCTsoEYKLiuRChungTWHChuMYet al.. Triple combination of interferon beta-1b, lopinavirâ€&quot;ritonavir, and" exact="ribavirin" post="in the treatment of patients admitted to hospital with"/>
 <result pre="(2019-nCoV). Biosci Trends. (2020) 14:69â€&quot;71. 10.5582/bst.2020.0102031996494 112.WangMCaoRZhangLYangXLiuJXuMet al.. Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
 <result pre="in vitro. Cell Res. (2020) 30:269â€&quot;71. 10.1038/s41422-020-0282-032020029 113.ChenZHuJZhangZJiangSHanSYanDet al.Efficacy of" exact="hydroxychloroquine" post="in patients with COVID-19: results of a randomized clinical"/>
 <result pre="trial. medRxiv. (2020). 10.1101/2020.03.22.20040758. [Epub ahead of print]. 114.MehraMRRuschitzkaFPatelANRetractionâ€&quot;Hydroxychloroquine or" exact="chloroquine" post="with or without a macrolide for treatment of COVID-19:"/>
</results>
